United States - English - NLM (National Library of Medicine)

lake erie medical dba quality care products llc - diclofenac sodium (unii: qtg126297q) (diclofenac - unii:144o8ql0l1) - voltaren® gel is indicated for the relief of the pain of osteoarthritis of joints amenable to topical treatment, such as the knees and those of the hands. - voltaren® gel has not been evaluated for use on the spine, hip, or shoulder. the use of voltaren® gel is contraindicated in patients with a known hypersensitivity to diclofenac. voltaren® gel should not be administered in patients who have experienced asthma, urticaria, or other allergic-type reactions after taking aspirin or other nsaids. severe, rarely fatal, anaphylactic-like reactions to nsaids have been reported in such patients [see warnings and precautions (5.1)]. voltaren® gel is contraindicated in the setting of coronary artery bypass graft (cabg) surgery [see warnings and precautions (5.1 )] . the safety of voltaren® gel has not been established during pregnancy. there are no well-controlled studies of diclofenac in pregnant women. human and animal studies indicate that diclofenac crosses the placenta. in late pregnancy, as with other nsaids, v

United States - English - NLM (National Library of Medicine)

physicians total care, inc. - diclofenac sodium (unii: qtg126297q) (diclofenac - unii:144o8ql0l1) - diclofenac sodium 10 mg in 1 g - voltaren® gel is indicated for the relief of the pain of osteoarthritis of joints amenable to topical treatment, such as the knees and those of the hands. - voltaren® gel has not been evaluated for use on the spine, hip, or shoulder. the use of voltaren® gel is contraindicated in patients with a known hypersensitivity to diclofenac. voltaren® gel should not be administered in patients who have experienced asthma, urticaria, or other allergic-type reactions after taking aspirin or other nsaids. severe, rarely fatal, anaphylactic-like reactions to nsaids have been reported in such patients [see warnings and precautions (5.1)]. voltaren® gel is contraindicated in the setting of coronary artery bypass graft (cabg) surgery [see   warnings and precautions (5.1 )] . the safety of voltaren® gel has not been established during pregnancy. there are no well-controlled studies of diclofenac in pregnant women. human and animal studies indicate that diclofenac crosses the placenta. in late pregnancy, as with other nsaids,

United States - English - NLM (National Library of Medicine)

stat rx usa llc - diclofenac sodium (unii: qtg126297q) (diclofenac - unii:144o8ql0l1) - diclofenac sodium 10 mg in 1 g - voltaren® gel is indicated for the relief of the pain of osteoarthritis of joints amenable to topical treatment, such as the knees and those of the hands. - voltaren® gel has not been evaluated for use on the spine, hip, or shoulder. the use of voltaren® gel is contraindicated in patients with a known hypersensitivity to diclofenac. voltaren® gel should not be administered in patients who have experienced asthma, urticaria, or other allergic-type reactions after taking aspirin or other nsaids. severe, rarely fatal, anaphylactic-like reactions to nsaids have been reported in such patients [see warnings and precautions (5.1)]. voltaren® gel is contraindicated in the setting of coronary artery bypass graft (cabg) surgery [see   warnings and precautions (5.1 )] . the safety of voltaren® gel has not been established during pregnancy. there are no well-controlled studies of diclofenac in pregnant women. human and animal studies indicate that diclofenac crosses the placenta. in late pregnancy, as with other nsaids,

United States - English - NLM (National Library of Medicine)

keltman pharmaceuticals inc. - diclofenac sodium (unii: qtg126297q) (diclofenac - unii:144o8ql0l1) - diclofenac sodium 10 mg in 1 g - voltaren® gel is indicated for the relief of the pain of osteoarthritis of joints amenable to topical treatment, such as the knees and those of the hands. - voltaren® gel has not been evaluated for use on the spine, hip, or shoulder. the use of voltaren® gel is contraindicated in patients with a known hypersensitivity to diclofenac. voltaren® gel should not be administered in patients who have experienced asthma, urticaria, or other allergic-type reactions after taking aspirin or other nsaids. severe, rarely fatal, anaphylactic-like reactions to nsaids have been reported in such patients [see warnings and precautions (5.1)]. voltaren® gel is contraindicated in the setting of coronary artery bypass graft (cabg) surgery [see   warnings and precautions (5.1 )] . the safety of voltaren® gel has not been established during pregnancy. there are no well-controlled studies of diclofenac in pregnant women. human and animal studies indicate that diclofenac crosses the placenta. in late pregnancy, as with other nsaids,

United States - English - NLM (National Library of Medicine)

stat rx usa llc - diclofenac sodium (unii: qtg126297q) (diclofenac - unii:144o8ql0l1) - voltaren® gel is indicated for the relief of the pain of osteoarthritis of joints amenable to topical treatment, such as the knees and those of the hands. • voltaren® gel has not been evaluated for use on the spine, hip, or shoulder. the use of voltaren® gel is contraindicated in patients with a known hypersensitivity to diclofenac. voltaren® gel should not be administered in patients who have experienced asthma, urticaria, or other allergic-type reactions after taking aspirin or other nsaids. severe, rarely fatal, anaphylactic-like reactions to nsaids have been reported in such patients [see warnings and precautions (5.1)]. voltaren® gel is contraindicated in the setting of coronary artery bypass graft (cabg) surgery [see warnings and precautions (5.1)]. the safety of voltaren® gel has not been established during pregnancy. there are no well-controlled studies of diclofenac in pregnant women. human and animal studies indicate that diclofenac crosses the placenta. in late pregnancy, as with other nsaids, volt

Australia - English - Department of Health (Therapeutic Goods Administration)

arrow pharma pty ltd - captopril, quantity: 50 mg - tablet, uncoated - excipient ingredients: microcrystalline cellulose; stearic acid; maize starch; lactose monohydrate - 1.hypertension: capoten (captopril) is indicated for the treatment of hypertension. in using capoten, consideration should be given to the risk of neutropenia/agranulocytosis (see precautions). capoten is effective alone and in combination with other antihypertensive agents, especially thiazide-type diuretics. the blood pressure lowering effects of captopril and thiazides are approximately additive. 2. myocardial infarction: capoten is indicated to improve survival following myocardial infarction in clinically stable patients with left ventricular dysfunction manifested as an ejection fraction less than or equal to 40%, and to reduce the incidence of overt heart failure and subsequent hospitalisations for congestive heart failure in these patients. the efficacy data for the use of captopril following myocardial infarction are strongest for initiation of therapy beyond 3 days post-infarct. 3. heart failure: capoten (captopril) is indicated for the treatment of heart failure. in symptomatic patients it is recom

Australia - English - Department of Health (Therapeutic Goods Administration)

arrow pharma pty ltd - captopril, quantity: 25 mg - tablet, uncoated - excipient ingredients: lactose monohydrate; stearic acid; microcrystalline cellulose; maize starch - 1.hypertension: capoten (captopril) is indicated for the treatment of hypertension. in using capoten, consideration should be given to the risk of neutropenia/agranulocytosis (see precautions). capoten is effective alone and in combination with other antihypertensive agents, especially thiazide-type diuretics. the blood pressure lowering effects of captopril and thiazides are approximately additive. 2. myocardial infarction: capoten is indicated to improve survival following myocardial infarction in clinically stable patients with left ventricular dysfunction manifested as an ejection fraction less than or equal to 40%, and to reduce the incidence of overt heart failure and subsequent hospitalisations for congestive heart failure in these patients. the efficacy data for the use of captopril following myocardial infarction are strongest for initiation of therapy beyond 3 days post-infarct. 3. heart failure: capoten (captopril) is indicated for the treatment of heart failure. in symptomatic patients it is recom

New Zealand - English - Medsafe (Medicines Safety Authority)

novartis new zealand ltd - diclofenac sodium 1 mg/ml;   - eye drops, solution - 300 mcg/0.3ml - active: diclofenac sodium 1 mg/ml   excipient: boric acid polyoxyl 35 castor oil trometamol water for injection - voltaren ophtha eye drops are indicated for: · post-operative inflammation in cataract surgery and other surgical interventions. · prevention of cystoid macular oedema after cataract extraction with lens implantation. · post-traumatic inflammation in non-penetrating wounds. · inhibition of miosis in cataract surgery. · relief of pain and photophobia. · non-infected inflammatory conditions of the anterior segment of the eye.

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - irbesartan, quantity: 75 mg - tablet, film coated - excipient ingredients: polysorbate 80; macrogol 6000; magnesium stearate; sodium starch glycollate type b; microcrystalline cellulose; colloidal anhydrous silica; hypromellose; lactose monohydrate - indicated for the treatment of hypertension.,indicated for delaying the progression of renal disease in hypertensive type ii diabetics with persistent micro-albuminuria (equal to or greater than 30mg per 24 hours) or urinary protein in excess of 900mg per 24 hours.

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - irbesartan, quantity: 150 mg - tablet, film coated - excipient ingredients: colloidal anhydrous silica; lactose monohydrate; macrogol 6000; microcrystalline cellulose; sodium starch glycollate type b; hypromellose; magnesium stearate; polysorbate 80 - indicated for the treatment of hypertension.,indicated for delaying the progression of renal disease in hypertensive type ii diabetics with persistent micro-albuminuria (equal to or greater than 30mg per 24 hours) or urinary protein in excess of 900mg per 24 hours.